Alan J. Tuchman

Insider Reports History

Location: Mahopac, NY
Owner filing signature: /s/ Robert Weinstein, Attorney-in-fact
Transaction evidence: Report rows are grouped by the transaction date disclosed in the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Alan J. Tuchman

Form 4 holding Chief Medical Officer, Director

Synaptogenix, Inc.

Security class: Common Stock, par value $0.0001 per share
Shares / value: 3,909
Estimated value: $30,685
Report date: 30 Jun 2025
Price: $7.85
Ownership: Direct

Form 4 holding Chief Medical Officer, Director

TAO Synergies Inc.

Security class: Employee Stock Option (right to buy)
Shares / value: 2,000
Estimated value
Report date: 06 Aug 2025
Price
Ownership: Direct
Underlying class: Common Stock
Underlying amount

Insider Reports Filed by Alan J. Tuchman

5 TAOX

TAO Synergies Inc.

Report period: 31 Dec 2025
Transactions: 1
Transaction value: $0
Accepted by SEC: 05 Feb 2026, 17:14
Role: Chief Medical Officer, Director
Next action: Open filing details

4 SNPX

TAO Synergies Inc.

Report period: 30 Jun 2025
Transactions: 2
Transaction value: -$13,549
Accepted by SEC: 02 Jul 2025, 16:05
Role: Chief Medical Officer, Director
Next action: Open filing details

4 SNPX

Synaptogenix, Inc.

Report period: 16 Dec 2022
Transactions: 1
Transaction value: -$31,641
Accepted by SEC: 20 Dec 2022, 19:00
Role: Chief Executive Officer, Director
Next action: Open filing details

4/A SNPX

Synaptogenix, Inc.

Report period: 15 Nov 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 01 Dec 2022, 18:46
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNPX

Synaptogenix, Inc.

Report period: 16 Feb 2022
Transactions: 1
Transaction value: $0
Accepted by SEC: 22 Feb 2022, 16:01
Role: Chief Executive Officer, Director
Next action: Open filing details

4 SNPX

Synaptogenix, Inc.

Report period: 13 Jul 2021
Transactions: 1
Transaction value: $0
Accepted by SEC: 15 Jul 2021, 18:08
Role: Chief Executive Officer, Director
Next action: Open filing details

3 SNPX

Synaptogenix, Inc.

Report period: 04 Jun 2021
Transactions: 0
Transaction value: $0
Accepted by SEC: 14 Jun 2021, 20:14
Role: Chief Executive Officer, Director
Next action: Open filing details

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. to update or revoke optional consent for future visits. For more information, see our Privacy Policy .